Core Insights - QuidelOrtho's shares fell 12.8% after disappointing Q3 financial results and a reduced full-year earnings forecast [1] - The company's Q3 revenue was $699.9 million, a 3.7% decrease year-over-year, despite adjusted earnings per share of $0.80 beating Wall Street expectations [1] - A significant GAAP net loss, including a non-cash goodwill impairment charge, raised investor concerns [1] - QuidelOrtho lowered its adjusted earnings per share guidance for the full year by 10.6% at the midpoint [1] Market Reaction - QuidelOrtho's shares have shown extreme volatility, with 35 moves greater than 5% in the past year, indicating significant market impact from recent news [3] - The previous notable stock movement occurred 17 days prior, when shares gained 5.5% following positive news regarding the company's commitment to transfusion medicine and FDA approval of a new product [4] Stock Performance - Since the beginning of the year, QuidelOrtho's stock has declined by 47.9%, currently trading at $23.47, which is 50.7% below its 52-week high of $47.61 [5] - An investment of $1,000 in QuidelOrtho shares five years ago would now be worth $82.80 [5]

Core Insights - QuidelOrtho Corporation will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A conference call to discuss the financial results will take place at 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - The company is recognized as a global leader in in vitro diagnostics, focusing on advancing diagnostic solutions to improve patient outcomes [4] Financial Reporting - The financial results for the third quarter ended September 28, 2025, will be released after market hours on November 5, 2025 [1] - A conference call will be held to discuss these results, accessible via the company's Investor Relations page [2] Company Overview - QuidelOrtho specializes in various diagnostic fields, including clinical chemistry, immunoassay, immunohematology, and molecular testing [4] - The company aims to deliver fast, accurate, and reliable diagnostic results to enhance patient care across different healthcare settings [4]